Synonym
Gemopatrilat; BMS 189921; BMS-189921; BMS189921.
IUPAC/Chemical Name
(6S)-Hexahydro-6-((alphaS)-alpha-mercaptohydrocinnamamido)-2,2-dimethyl-7-oxo-1H-azepine-1-acetic acid
InChi Key
YRSVDSQRGBYVIY-GJZGRUSLSA-N
InChi Code
InChI=1S/C19H26N2O4S/c1-19(2)10-6-9-14(18(25)21(19)12-16(22)23)20-17(24)15(26)11-13-7-4-3-5-8-13/h3-5,7-8,14-15,26H,6,9-12H2,1-2H3,(H,20,24)(H,22,23)/t14-,15-/m0/s1
SMILES Code
CC1(C)CCC[C@H](NC(=O)[C@@H](S)Cc2ccccc2)C(=O)N1CC(=O)O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
378.49
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Wait JC, Vaccharajani N, Mitroka J, Jemal M, Khan S, Bonacorsi SJ, Rinehart JK, Iyer RA. Metabolism of [14C]gemopatrilat after oral administration to rats, dogs, and humans. Drug Metab Dispos. 2006 Jun;34(6):961-70. Epub 2006 Mar 15. PubMed PMID: 16540589.
2: Singh J, Kronenthal DR, Schwinden M, Godfrey JD, Fox R, Vawter EJ, Zhang B, Kissick TP, Patel B, Mneimne O, Humora M, Papaioannou CG, Szymanski W, Wong MK, Chen CK, Heikes JE, DiMarco JD, Qiu J, Deshpande RP, Gougoutas JZ, Mueller RH. Efficient asymmetric synthesis of the vasopeptidase inhibitor BMS-189921. Org Lett. 2003 Aug 21;5(17):3155-8. PubMed PMID: 12917005.
3: Laverman GD, Van Goor H, Henning RH, De Jong PE, De Zeeuw D, Navis G. Renoprotective effects of VPI versus ACEI in normotensive nephrotic rats on different sodium intakes. Kidney Int. 2003 Jan;63(1):64-71. PubMed PMID: 12472769.
4: Sagnella GA. Vasopeptidase inhibitors. J Renin Angiotensin Aldosterone Syst. 2002 Jun;3(2):90-5. Review. PubMed PMID: 12228848.
5: Hubner RA, Kubota E, Casley DJ, Johnston CI, Burrell LM. In-vitro and in-vivo inhibition of rat neutral endopeptidase and angiotensin converting enzyme with the vasopeptidase inhibitor gemopatrilat. J Hypertens. 2001 May;19(5):941-6. PubMed PMID: 11393678.
